RFEM’s Biosimilars IPR Dashboard provides current information on IPR proceedings related to proposed biosimilar...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
Herceptin®
-
-
As we previously reported here and here, Celltrion filed suit against Genentech seeking declaratory judgment that a host of patents...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As we previously reported here and here, Celltrion filed suit against Genentech seeking declaratory judgment that a number of patents...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
In October, we reported on a growing number of IPR challenges to Genentech’s U.S. Patent No. 6,407,213 (“the ʼ213 patent”) to...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
We previously reported that on January 11, 2018, Celltrion, Inc., Celltrion Healthcare, Co. Ltd. (collectively “Celltrion”), Teva...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On January 11, 2018, Celltrion, Inc., Celltrion Healthcare, Co. Ltd. (collectively “Celltrion”), Teva Pharmaceuticals International...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The FDA has only approved eight biosimilar products to date. The second most recently approved biosimilar is Mvasi (bevacizumab-awwb),...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As previously reported, earlier this year Celltrion, Inc. (“Celltrion”) filed petitions seeking inter partes review (“IPR”) of...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Samsung Bioepis (“Bioepis”) has joined a growing list of challengers to Genentech’s U.S. Patent No. 6,407,213 (“the ʼ213...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]